3D Signatures, MDxHealth Partner to Develop Less-invasive Telo-PC Prognostic Test

3D Signatures, MDxHealth Partner to Develop Less-invasive Telo-PC Prognostic Test
A new, minimally invasive prognostic test to improve treatment of prostate cancer, called Telo-PC, will be developed following the establishment of a collaborative agreement between 3D Signatures and Belgium-based MDxHealth. Prostate cancer diagnosis traditionally requires repeated invasive tissue biopsies, which do not guarantee the successful detection of tumor cells and may misdiagnose benign conditions as

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *